Objectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test. Results. Resveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well. Conclusion. These findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure.

中文翻译：

---

白藜芦醇治疗射血分数降低的心力衰竭患者的血液流变学改变。

目标。白藜芦醇的几种有益作用已经发表。本研究评估了白藜芦醇对射血分数降低的心力衰竭患者血液流变学参数的影响。方法。在我们的双盲、安慰剂对照人体临床试验中，我们招募了 60 名心力衰竭门诊患者。患者被随机分为两组：每天服用 100 毫克白藜芦醇胶囊或服用安慰剂 3 个月。通过微量血细胞比容离心机测定血细胞比容。通过毛细管粘度计评估血浆和全血粘度。通过 LORCA 和 Myrenne 聚集仪测量红细胞聚集。LORCA ektacytometer 用于测量红细胞变形能力。通过 6 分钟步行测试评估运动能力。结果。白藜芦醇治疗对血细胞比容和粘度没有任何显着影响。红细胞变形能力也保持不变。然而，与 3 个月后的基线相比，白藜芦醇组的红细胞聚集显着改善。此外，运动能力与血液流变学特性（Hct、WBV、RBC 聚集和变形能力）之间也存在正相关。结论。这些发现表明，白藜芦醇可以显着减少红细胞聚集，这可能对微循环产生积极影响，这可能有助于改善心力衰竭的组织灌注和氧气供应。